VASCULAR ENDOTHELIAL GROWTH FACTOR VEGF-A AS A MARKER OF ENDOTHELIAL DYSFUNCTION ASSOCIATED WITH SEVERE COVID-19 IN PATIENTS WITH CHRONIC CONCOMITANT PATHOLOGY

Аннотация

This study addresses the significance of vascular endothelial growth factor A (VEGF-A) as a potential biomarker of endothelial dysfunction in individuals with severe manifestations of COVID-19, particularly those with pre-existing chronic comorbidities such as diabetes mellitus, hypertension, obesity, and cardiovascular diseases. Endothelial dysfunction has emerged as a key pathological feature in severe SARS-CoV-2 infection, contributing to a range of complications including microthrombosis, exaggerated vascular permeability, and systemic inflammatory responses.The assessment of circulating VEGF-A levels in COVID-19 patients may serve as an early indicator of disease severity and endothelial injury, offering potential utility in risk stratification, prognosis, and therapeutic decision-making. Moreover, VEGF-A could be explored as a target for adjunctive therapy, aiming to mitigate endothelial dysfunction and its clinical consequences in high-risk patient populations.